Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicamtiv (MYK-491) Phase 1 in Healthy Volunteers
NCT03062956Phase 1Completed
- Sponsor
- MyoKardia
- Start
- Jan 2017
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in dilated cardiomyopathy (DCM) comparing Single oral dose of MYK-491 with Single oral dose of placebo (2 arms). Primary endpoint: Safety and tolerability assessments at 7 days. Started Jan 2017; status: completed.
02
Drugs
danicamtiv
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT03062956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03062956.